Intracoronary Delivery of Porcine Cardiac Progenitor Cells Overexpressing IGF-1 and HGF in a Pig Model of Sub-Acute Myocardial Infarction
Cristina Prat-Vidal,
Verónica Crisóstomo,
Isabel Moscoso,
Claudia Báez-Díaz,
Virginia Blanco-Blázquez,
Guadalupe Gómez-Mauricio,
Guillermo Albericio,
Susana Aguilar,
María-Eugenia Fernández-Santos,
Francisco Fernández-Avilés,
Francisco M. Sánchez-Margallo,
Antoni Bayes-Genis,
Antonio Bernad
Affiliations
Cristina Prat-Vidal
ICREC Research Program, Germans Trias i Pujol Health Science Research Institute, Can Ruti Campus, Heart Institute (iCor), Germans Trias i Pujol University Hospital, 08916 Badalona, Spain
Verónica Crisóstomo
CIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain
Isabel Moscoso
CIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain
Claudia Báez-Díaz
CIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain
Virginia Blanco-Blázquez
CIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain
Guadalupe Gómez-Mauricio
Jesús Usón Minimally Invasive Surgery Center, 10071 Cáceres, Spain
Guillermo Albericio
Immunology and Oncology Department, National Center for Biotechnology, 28049 Madrid, Spain
Susana Aguilar
Immunology and Oncology Department, National Center for Biotechnology, 28049 Madrid, Spain
María-Eugenia Fernández-Santos
CIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain
Francisco Fernández-Avilés
CIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain
Francisco M. Sánchez-Margallo
CIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain
Antoni Bayes-Genis
ICREC Research Program, Germans Trias i Pujol Health Science Research Institute, Can Ruti Campus, Heart Institute (iCor), Germans Trias i Pujol University Hospital, 08916 Badalona, Spain
Antonio Bernad
Immunology and Oncology Department, National Center for Biotechnology, 28049 Madrid, Spain
Human cardiac progenitor cells (hCPC) are considered a good candidate in cell therapy for ischemic heart disease, demonstrating capacity to improve functional recovery after myocardial infarction (MI), both in small and large preclinical animal models. However, improvements are required in terms of cell engraftment and efficacy. Based on previously published reports, insulin-growth factor 1 (IGF-1) and hepatocyte growth factor (HGF) have demonstrated substantial cardioprotective, repair and regeneration activities, so they are good candidates to be evaluated in large animal model of MI. We have validated porcine cardiac progenitor cells (pCPC) and lentiviral vectors to overexpress IGF-1 (co-expressing eGFP) and HGF (co-expressing mCherry). pCPC were transduced and IGF1-eGFPpos and HGF-mCherrypos populations were purified by cell sorting and further expanded. Overexpression of IGF-1 has a limited impact on pCPC expression profile, whereas results indicated that pCPC-HGF-mCherry cultures could be counter selecting high expresser cells. In addition, pCPC-IGF1-eGFP showed a higher cardiogenic response, evaluated in co-cultures with decellularized extracellular matrix, compared with native pCPC or pCPC-HGF-mCherry. In vivo intracoronary co-administration of pCPC-IGF1-eGFP and pCPC-HFG-mCherry (1:1; 40 × 106/animal), one week after the induction of an MI model in swine, revealed no significant improvement in cardiac function.